Form 4: Intensity Therapeutics Principal Accounting Officer Boosts Stake Through Employee Stock Purchase Plan

Intensity Therapeutics' Principal Accounting Officer, John M. Wesolowski, acquired 69,745 shares of common stock at $0.261 per share through the company's 2024 Employee Stock Purchase Plan.

Summary

• John M. Wesolowski, Principal Accounting Officer of Intensity Therapeutics, Inc. (INTS), acquired 69,745 shares of common stock.
• The acquisition occurred on June 30, 2025, at a price of $0.261 per share.
• The shares were purchased under the company's 2024 Employee Stock Purchase Plan (ESPP).
• The purchase price represents 85% of the common stock's closing price on June 30, 2025.
• Following this transaction, Wesolowski beneficially owns a total of 76,436 shares of Intensity Therapeutics common stock.
• The transaction is exempt under SEC Rules 16b-3(c) and 16b-3(d).

Sentiment

Score: 7

Explanation: The acquisition of shares by a Principal Accounting Officer, even through an ESPP, generally indicates a positive signal of insider confidence in the company's future, although the low share price at which the transaction occurred could be a minor concern.

Positives

• An insider, the Principal Accounting Officer, increased their stake in the company, which can signal confidence in the company's future prospects.
• The acquisition was made through an Employee Stock Purchase Plan (ESPP), indicating participation in an employee benefit program.

Negatives

• The purchase price of $0.261 per share, which is 85% of the closing price, suggests a relatively low stock price, though this is a feature of ESPPs.

Future Outlook

The document does not provide forward-looking statements or guidance, as it is a report of a past insider transaction.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends. It reflects an internal employee stock purchase rather than a strategic industry move.

Comparison to Industry Standards

• This document reports an individual insider stock acquisition through an ESPP, which is a standard employee benefit. It does not contain information that allows for a direct comparison of company performance or financial results against industry benchmarks or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: May view the insider purchase as a positive signal of confidence.
• Employees: The existence of an ESPP benefits employees by allowing them to purchase company stock at a discount.

Key Dates

Keywords

Intensity Therapeutics, INTS, Form 4, Insider Trading, Stock Acquisition, Employee Stock Purchase Plan, ESPP, John M. Wesolowski, Principal Accounting Officer, Beneficial Ownership